2. Academic Validation
  3. A human monoclonal antibody blocking SARS-CoV-2 infection

A human monoclonal antibody blocking SARS-CoV-2 infection

  • Nat Commun. 2020 May 4;11(1):2251. doi: 10.1038/s41467-020-16256-y.
Chunyan Wang  # 1,  Wentao Li  # 1,  Dubravka Drabek  # 2 3,  Nisreen M A Okba 4,  Rien van Haperen 2 3,  Albert D M E Osterhaus 5,  Frank J M van Kuppeveld 1,  Bart L Haagmans 4,  Frank Grosveld 2 3,  Berend-Jan Bosch 6
Affiliations

Affiliations

  • 1 Virology Section, Infectious Diseases and Immunology Division, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands.
  • 2 Department of Cell Biology, Erasmus Medical Center, Rotterdam, the Netherlands.
  • 3 Harbour BioMed, Rotterdam, the Netherlands.
  • 4 Department of Viroscience, Erasmus Medical Center, Rotterdam, the Netherlands.
  • 5 University of Veterinary Medicine, Hannover, Germany.
  • 6 Virology Section, Infectious Diseases and Immunology Division, Department of Biomolecular Health Sciences, Faculty of Veterinary Medicine, Utrecht University, Utrecht, the Netherlands. b.j.bosch@uu.nl.
  • # Contributed equally.
PMID: 32366817 DOI: 10.1038/s41467-020-16256-y
Abstract

The emergence of the novel human coronavirus SARS-CoV-2 in Wuhan, China has caused a worldwide epidemic of respiratory disease (COVID-19). Vaccines and targeted therapeutics for treatment of this disease are currently lacking. Here we report a human monoclonal antibody that neutralizes SARS-CoV-2 (and SARS-CoV) in Cell Culture. This cross-neutralizing antibody targets a communal epitope on these viruses and may offer potential for prevention and treatment of COVID-19.

Figures
Products